查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
单纯疱疹病毒治疗市场 - 2018-2028年全球行业规模、份额、趋势、机会和预测，按病毒类型、治疗方法、给药途径、分销渠道和地区划分
市场调查报告书
商品编码
1303451

单纯疱疹病毒治疗市场 - 2018-2028年全球行业规模、份额、趋势、机会和预测，按病毒类型、治疗方法、给药途径、分销渠道和地区划分

Herpes Simplex Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Virus Type, By Treatment, By Route of Administration, By Distribution Channel, By Region
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球单纯疱疹病毒（HSV）治疗市场预计将在预测期内见证令人瞩目的增长。这可以归因于人口老龄化的增长和单纯疱疹感染和艾滋病毒等疾病病例的增加。此外，新兴国家越来越多地使用不卫生的做法，以及对研究和开发活动的投资增加，都大大增加了全球不同地区对单纯疱疹病毒治疗的需求。此外，对罕见病症有效治疗的需求不断增长，预计将进一步增加对单纯疱疹病毒治疗的需求，从而推动到2028年的市场增长。此外，人们对使用新疗法优势的认识不断提高，加上全球各地对HSV治疗的医疗支出不断增加，预计在预测期内将进一步支持单纯疱疹病毒治疗市场。

HSV感染的流行率不断提高

单纯疱疹病毒感染患病率的增加，以及医院获得性感染率的增加和微生物的快速变异导致的新菌株，是在预测期内推动市场增长的主要因素。此外，在不发达和发展中地区，传染病传播的增加和清洁度的缺乏，在预测期内进一步推动了单纯疱疹病毒感染治疗市场。根据世界卫生组织的数据，感染HSV-2的女性多于男性。2012年，估计有2.67亿女性和1.5亿男性感染了这种病毒。HSV脑炎负担的上升预计将推动这一领域的市场发展。此外，对药物开发的关注度上升，对精准医疗的需求增加，以及家庭护理环境和护理点诊断的高度采用，对研发活动的投资增加，预计将在预测期内推动全球市场增长。

不断增长的医疗保健支出

随着技术创新、医疗保健支出的增加以及医疗保健设施和系统的改善，制药和医疗保健部门正在迅速发展，这预计将在预测期内创造有利可图的增长。全球许多医院、非住院手术护理中心和诊所都在采用先进的设备和器材，这将促进市场的增长。越来越多的倡议和研究机构之间的合作正在促进针对病毒的新型治疗方案的开发，这预计将在预测期内促进市场增长。2020年1月，来自瑞士洛桑EPFL、日内瓦大学（UNIGE）和曼彻斯特大学的科学家们通过研究合作，开发出了由糖制成的新型抗病毒材料 - virucides，显示出治疗单纯疱疹（冷疮病毒）的前景。

可用的定制

利用给定的市场数据，TechSci Research根据公司的具体需要提供定制服务。该报告可提供以下定制选项：

公司信息

  • 其他市场参与者（最多5家）的详细分析和概况。

目录

第一章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 研究考虑的年份
    • 关键的市场细分

第二章：研究方法

  • 研究的目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二级来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第三章：执行摘要

  • 市场概述
  • 主要市场细分概述
  • 主要市场参与者概述
  • 主要地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第四章：客户的声音

第五章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管线细目
  • 按状态分类的管线细目
  • 按研究应用分类的管线细目
  • 按地区分類的管线细目
  • 临床试验热图

第六章：全球单纯疱疹病毒（HSV）治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额与预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按地区
    • 按公司分类 (2022年)
  • 市场地图
    • 按病毒类型分类
    • 按治疗方法分类
    • 按给药途径分类
    • 按销售渠道分类

第七章：北美单纯疱疹病毒（HSV）治疗市场展望

  • 市场规模和预测
    • 按价值分类
  • 市场份额和预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按国家分类
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第八章：欧洲单纯疱疹病毒（HSV）治疗市场前景

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按国家分类
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第九章：亚太地区单纯疱疹病毒（HSV）治疗市场前景

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按国家分类
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第十章：南美单纯疱疹病毒（HSV）治疗市场前景

  • 市场规模和预测
    • 按价值计算
  • 市场份额和预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按国家分类
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第11章 ：中东和非洲单纯疱疹病毒（HSV）治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额和预测
    • 按病毒类型（HSV-1 v/ HSV-2）分类
    • 按治疗方法（药物和/或疫苗）分类
    • 按给药途径（口服、静脉注射、外用）分类
    • 按销售渠道（医院药店、零售药店、网上药店）分类
    • 按国家分类
  • MEA: 国家分析
    • 南非 单纯疱疹病毒（HSV）治疗
    • 沙特阿拉伯 单纯疱疹病毒（HSV）治疗
    • 阿联酋 单纯疱疹病毒（HSV）治疗

第十二章 ：市场动态

  • 驱动因素
  • 挑战

第十三章 ：市场趋势与发展

  • 最近的发展情况
  • 合併和收购
  • 产品发布

第十四章：竞争格局

  • 业务概况 公司简介 产品与服务 财务状况（如报告所示） 近期发展 SWOT分析
    • Novartis International AG
    • GlaxoSmithKline, plc.
    • Sanofi SA
    • Mylan N.V.
    • Emcure Pharmaceuticals Ltd.
    • Glenmark Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Apotex Inc.
    • Viatris Inc.
    • Teva Pharmaceuticals Industries Ltd

第十五章：战略建议

简介目录
Product Code: 14594

Global Herpes Simplex Virus (HSV) Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing aging population and increased cases of diseases like Herpes Simplex infection and HIV. Additionally, the growing usage of unhygienic practices in emerging countries, along with rising investments in research and development activities, have significantly increased the demand for herpes simplex virus treatment across different parts of the globe. Moreover, the growing demand for efficient treatment for rare conditions is further expected to increase the demand for herpes simplex virus treatment, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using new treatments, along with increasing healthcare expenditure on HSV treatment across the globe, is further expected to support the herpes simplex virus treatment market during the forecast period.

Increasing prevalence of HSV Infection

The increasing prevalence of Herpes Simplex Virus infection, along with the increasing rate of hospital-acquired infection and rapid mutations in the microorganism leading to new strains, are the major factors that will drive the growth of the market during the forecast period. Furthermore, the increasing transmission of infectious disease and lack of cleanliness in underdeveloped and developing regions are further propelling the herpes simplex virus infection treatment market during the forecast period. According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection. The rising burden of HSV encephalitis is expected to propel the market in this segment. As per the National Organization for Rare Disorders, the prevalence of acute encephalitis in the U.S. is around 2,000 cases per year, and it includes around 10% of total cases of encephalitis occurring in the U.S. Additionally, the rising focus on drug development, increasing demand for precision medicine along with high adoption of home care settings and point-of-care diagnostics, growing investments in research and development activities are expected to drive global market growth during the forecast period.

Growing Healthcare Expenditure

The pharma and healthcare sector are rapidly growing with technological innovations, increasing healthcare spending, and improving healthcare facilities and systems, which is expected to create lucrative growth during the forecast period. Many hospitals, ambulatory surgical care centers, and clinics are adopting advanced devices and equipment across the globe, which will enhance the growth of the market. Increasing initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is expected to boost market growth during the forecast period. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).

Market Segmentation

The global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, treatment, route of administration, distribution channel, and by region. Based on the virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global herpes simplex virus treatment market on account of the growing demand for treatments due to the increasing prevalence of herpes simplex virus infection.

Market Players

Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.

Report Scope

In this report, Global Herpes Simplex Virus (HSV) Treatment systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:

  • HSV-1
  • HSV-2

Herpes Simplex Virus (HSV) Treatment Market, By Treatment:

  • Drugs
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Others
  • Vaccines
    • Simplirix
    • Others

Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Herpes Simplex Virus (HSV) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Herpes Simplex Virus (HSV) Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 6.2.2. By Treatment (Drugs v/s Vaccines)
      • 6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 6.2.2.2. By Vaccines (Simplirix, Others)
    • 6.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.5. By Region
    • 6.2.6. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Virus Type
    • 6.3.2. By Treatment
    • 6.3.3. By Route of Administration
    • 6.3.4. By Distribution Channel

7. North America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 7.2.2. By Treatment (Drugs v/s Vaccines)
      • 7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 7.2.2.2. By Vaccines (Simplirix, Others)
    • 7.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Virus Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Virus Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Virus Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 8.2.2. By Treatment (Drugs v/s Vaccines)
      • 8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 8.2.2.2. By Vaccines (Simplirix, Others)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Virus Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Virus Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Virus Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Virus Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Virus Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 9.2.2. By Treatment (Drugs v/s Vaccines)
      • 9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 9.2.2.2. By Vaccines (Simplirix, Others)
    • 9.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Virus Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Virus Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Virus Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Virus Type
        • 9.3.4.2.2. By Treatment
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Virus Type
        • 9.3.5.2.2. By Treatment
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 10.2.2. By Treatment (Drugs v/s Vaccines)
      • 10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 10.2.2.2. By Vaccines (Simplirix, Others)
    • 10.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Virus Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Virus Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Virus Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 11.2.2. By Treatment (Drugs v/s Vaccines)
      • 11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 11.2.2.2. By Vaccines (Simplirix, Others)
    • 11.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Virus Type
        • 11.3.1.2.2. By Treatment
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Virus Type
        • 11.3.2.2.2. By Treatment
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Virus Type
        • 11.3.3.2.2. By Treatment
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. Novartis International AG
    • 14.6.2. GlaxoSmithKline, plc.
    • 14.6.3. Sanofi SA
    • 14.6.4. Mylan N.V.
    • 14.6.5. Emcure Pharmaceuticals Ltd.
    • 14.6.6. Glenmark Pharmaceuticals Inc.
    • 14.6.7. Fresenius Kabi AG
    • 14.6.8. Apotex Inc.
    • 14.6.9. Viatris Inc.
    • 14.6.10. Teva Pharmaceuticals Industries Ltd

15. Strategic Recommendations